NAMS
NewAmsterdam Pharma Company N.V. Ordinary SharesNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.55B
P/E Ratio
—
EPS
$-1.78
Beta
0.08
52W High
$42.20
52W Low
$17.63
50-Day MA
$33.24
200-Day MA
$33.16
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V. is a cutting-edge biotechnology firm focused on creating innovative therapies for cardiometabolic diseases, leveraging its proprietary technology platform to address significant unmet medical needs. The company possesses a robust clinical development pipeline, underscored by its commitment to advancing treatment paradigms in this critical area of healthcare. With an experienced leadership team and a clear strategic vision for growth, NewAmsterdam presents a compelling investment opportunity for those seeking to be part of transformative healthcare solutions aimed at enhancing patient outcomes.
Fundamentals
| Revenue (TTM) | $22.57M |
| Gross Profit (TTM) | $22.57M |
| EBITDA | $-214.95M |
| Operating Margin | -1922.00% |
| Return on Equity | -29.50% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $0.19 |
| Book Value | $5.70 |
| Price-to-Book | 5.32 |
| Price-to-Sales (TTM) | 157.50 |
| EV/Revenue | 128.58 |
| EV/EBITDA | 27.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $116.90M |
| Float | $80.70M |
| % Insiders | 0.91% |
| % Institutions | 106.22% |
Historical Volatility
HV 10-Day
44.09%
HV 20-Day
47.20%
HV 30-Day
65.60%
HV 60-Day
60.47%
HV Rank
79.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($49.93 target)
3
Strong Buy10
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026